A cancer biologist's pipeline

Ziopharm Oncology Inc.'s deal last week to acquire the chemotherapeutic product indibulin from Baxter International Inc. is an example of how the company is using insights from molecular and cancer biology to identify in-licensing opportunities. Indibulin, re-named ZIO-301, is similar to taxanes but may have fewer side effects.

Like many NRDOs, ZIOP's pipeline strategy is to choose either compounds that have known efficacy in humans but come with safety limitations, or novel compounds against validated targets. Chairman and CEO

Read the full 795 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE